Acute severe colitis requires hospital admission for intravenous steroid therapy and close monitoring, due to potential life-threatening complications, such as perforation and toxic dilatation. [5] [6] [7] Up to 15% of patients present with acute severe disease. Clinical and laboratory severity markers predict the need for emergent colectomy and 85% of patients with .8 stools per day or 3 to 8 stools per day and raised C-reactive protein (CRP) of .45 mg/L on day 3 need urgent consideration of escalated medical therapy with rescue infliximab anti-tumor necrosis factor biologic therapy or intravenous cyclosporine or surgery. If medical therapy fails by day 7 or life-threatening complications occur, emergency colectomy with ileostomy is required as a lifesaving treatment. This clinical need for lifesaving and life-changing surgery unfolds rapidly and can be associated with postoperative psychosocial morbidity, especially in adolescent and young adult patients. [8] [9] [10] There is a need for novel rescue therapies for the treatment of acute severe colitis.
We previously demonstrated that oral delivery of Lactococcus lactis expressing an IL-27 hyperkine (LL-IL-27), composed of both EBI3 and p28 subunits, a linker molecule and secretary peptide, is immunosuppressive in murine chronic enterocolitis induced by CD4 + CD45Rb hi T-cell transfer. 11 In this T-cell-driven colitis model, representing adaptive immune responses, LL-IL-27 led to significant histologic improvement and survival advantage, through induction of IL-10 derived from intraepithelial mucosal T cells. We also described an immunosuppressive action on acute dextran sulfate sodium induced colitis, 11 although the mechanism was not explored. We then hypothesized that IL-27 may exert an immunosuppressive role in innate immune responses.
IL-27, a heterodimeric cytokine composed of EBI3 and p28 subunits, is secreted from antigen-presenting cells and signals through a heterodimeric receptor complex composed of the widely expressed Gp130 and the specific IL-27Ra. [12] [13] [14] IL-27 was initially considered proinflammatory through promotion of Th1 responses. 15 There is now appreciation that IL-27 has a wide functional repertoire, including profound antiinflammatory effects through the promotion of IL-10-secreting Tr1 regulatory T cells and inhibition of Th2 and Th17 responses. [12] [13] [14] Knowledge of IL-27 functionality has largely come from T-cell biology, and its role in the adaptive immune response is well described. [12] [13] [14] However, the IL-27 receptor complex is also expressed on other immune cell types, including granulocytes 16 and macrophages, 17 indicating that the functional capabilities of IL-27 may be even wider and in particular IL-27 may play a role in mediating innate immunity. Indeed, IL-27 can impact the function of innate cell subsets, including macrophages, 18 neutrophils, 16, 19 and dendritic cells (DCs). [20] [21] [22] It has been shown that IL-27 influences innate responses to bacterial challenge in the context of systemic sepsis in genetic manipulation models, such as IL-27Ra knockout murine strains. 23, 24 To date, there is no report on the immunosuppressive mechanism of IL-27 in acute inflammation of the colon driven by innate cells in a genetically intact, noninfective environment.
Here, by demonstrating an immunosuppressive effect of IL-27 on the innate, rather than adaptive, immune response in vivo in a genetically intact, noninfective, acute murine colitis model induced by intrarectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS), we offer novel mechanistic insights into the biology of IL-27 in vivo. Our data highlights the immunosuppressive role of IL-27 in innate immune responses, offering translational potential as a novel rescue therapy in acute severe colitis.
MATERIALS AND METHODS

Study Approval
Animal experiments were conducted under approved protocols by the National Cancer Institute Animal Care and Use Committee, in keeping with federal regulations governing care and use of animals in biomedical research. Frederick National Laboratory is accredited by AAALAC International and follows the Public Health Service Policy for the Care and Use of Laboratory Animals. Animal care was provided in accordance with the procedures outlined in the "Guide for Care and Use of Laboratory Animals" (National Research Council; 2011; National Academies Press; Washington, DC).
Animals
Experiments were performed on 6-to 10-week-old male SJL/J, B6 Rag 2/2 (01BJ2 -B6.129S7-Rag1) and B6 IL-10 2/2 (01IL6 -IL-10 GFP/C) mice, maintained within the National Cancer Institute Frederick animal facility. Mice were fed normal chow, had free access to water, and had exposure to a 12 hourly light/dark cycle.
Acute Colitis Induction
One hundred microliters of TNBS (;1 M in H2O, stored at 2208C, 92823; Sigma-Aldrich, St. Louis, MO) in 45% ethanol vehicle was administered intrarectally to isoflurane-anaesthetized mice with a 3-cm flexible catheter. The administered dose was optimized within our facility and dependent on the sensitivity of the mouse strain: 2 mg for SJL/J, 4 mg for B6/Rag 2/2 , and 6 mg for B6/IL-10 2/2 . The mice were held vertically for .30 seconds after instillation to ensure retention. Mice were given supportive care (wet food/ice chips/heat pad) throughout the protocol. Before colitis induction, mice were fasted to solid food overnight and given access to 5% sucrose water.
Bacterial Handling and Administration
L. lactis expressing IL-27 (LL-IL-27) and L. lactis empty vector control (LL-C) were prepared as described previously. 11 Briefly, L. lactis strain MG1363 was used for bacterial preparations. A bacterial research bank was prepared and IL-27 secretion confirmed by IL-27p28 enzyme-linked immunosorbent assay (ELISA) (M2728; R&D Systems, Minneapolis, MN) before storage in 50% glycerol at 2808C. For oral administration, stock bacteria were cultured 1:1000 in Difco M17 broth (218561; BD Biosciences, San Jose, CA) supplemented with 0.5% glucose and 5 mg/mL erythromycin (E5389; Sigma-Aldrich) (GM17E) at 308C for 16 hours. The bacteria were harvested by centrifugation and resuspended in buffered M9 salt media. Each mouse was administered 100 mL of this bacterial suspension by oral gavage at 24-hour intervals within the treatment protocol, commencing on the day of colitis induction following recovery from anesthesia.
Clinical Assessment of Colitis Activity
Disease activity index (DAI) was assessed daily as previously reported. 11 This is a composite score (maximum 12) of 3 parameters: weight loss from baseline (#1% 0, 1-#5% 1, 5-#10% 2, 10-#20% 3, .20% 4), consistency of stool (normal pellets 0, soft-semi formed 2, diarrhea 4), and presence of fecal blood (none 0, occult blood positive 2, overt blood 4). Macroscopic colitis score was assessed by colon weight (milligrams) and length (centimeter) immediately after harvest. A veterinary pathologist (M.R.A.) reported the histologic colitis score (maximum 14) based on multiple parameters: severity of inflammatory cell infiltrate (none 0, mild 1, moderate 2, severe 3), goblet cell depletion (none 0, mild 1, moderate 2, severe 3), crypt hyperplasia (none 0, mild 1, moderate 2, severe 3), degree of ulceration of epithelium (none 0, erosion 1, mild 2, moderate 3, severe 4 ulceration), and presence (1) or absence (0) of granulomas.
Measurement of Systemic Inflammatory Response
Blood was collected on day 2 after TNBS instillation in a serum separator tube, centrifuged, and the supernatant stored at 2808C for analysis. Serum CRP was measured using ELISA kit (2210-1; Life Diagnostics, Inc, West Chester, PA) as per instructions.
Gene Expression
RNA was extracted from cells or snap frozen distal colon tissue with the RNeasy mini kit (74104; Qiagen, Germantown, MD) as per instructions. Quality and yield were assessed by Nanodrop spectrophotometry. Complementary DNA was synthesized using the QuantiTect reverse transcription kit (205310; Qiagen) with inclusive genomic DNA wipeout buffer. Further details of gene expression assays are available in the supplementary materials.
Total Protein Extraction and Protein Expression Assays
Total protein was extracted by mechanical homogenization from distal colon tissue in 1· radioimmunoprecipitation assay buffer (Cell Signaling Technology, Beverly, MA 10, 9806) containing 1:1000 protease inhibitors at 48C. After 20 minutes of incubation on ice, tissue homogenates were centrifuged at 14,000 rpm for 10 minutes, and the supernatant was stored at 2808C for analysis. Total protein concentration was established using the Pierce BCA protein assay kit (23225) as compared with albumin standard. Further details of protein expression ELISA assays are available in the supplementary materials.
Colonic Lamina Propria Cell Isolation
Single-cell suspension from freshly harvested distal colon tissue was extracted with a lamina propria dissociation kit (130-097-410; Miltenyi Biotec, Auburn, CA) on the gentleMACS dissociator as per instructions, incorporating chemical and physical dissociations. 
Flow Cytometry and Cell Sorting
Macrophage Culture Protocols
Details of bone marrow-derived and thioglycollate peritoneal macrophage culture protocols are available in the supplementary materials and methods.
In Vitro Cell Stimulation Assay
Cells were stimulated with Escherichia coli 0111:B4-derived lipopolysaccharide (LPS) (L4130; Sigma-Aldrich) from 10 mg/mL stock, or 5 mM adenosine 5 0 -triphosphate disodium sate hydrate from 90 mM stock (A22383-5G; Sigma-Aldrich), stored at 2208C. Recombinant mouse IL-27 (NSO expressed, 2799-010/CF; R&D systems) was added to stimulation assay media as appropriate at 100 ng/mL. Culture supernatant was collected and stored at 2808C for analysis.
Statistics
SigmaPlot 11.0 (San Jose, CA) software was used for statistical analysis. Survival curves were analyzed according to the Kaplan-Meier estimator on GraphPad 6 (La Jolla, CA). Statistical differences were determined by analysis of variance and nonparametric rank sum tests, with P values of #0.05 considered to represent a statistically significant difference between the groups. If groups displayed normal variance, Student's t test was performed (as indicated in the figure legend text). Data are presented as mean 6 standard error of the mean.
RESULTS
IL-27 Attenuates Acute Severe Colitis In Vivo
Intrarectal instillation of TNBS in SJL/J mice resulted in an acute, severe, left-sided colitis, with a rapid increase in DAI within 24 hours. Mice treated with TNBS were included if their DAI was greater than 4 on day 1, reflecting appropriate response to TNBS. Mucosal delivery of LL-IL-27 attenuated TNBS colitis with a decreased DAI and significantly less weight loss from baseline weight, compared with L. lactis control (LL-C) ( Fig. 1A and B). LL-IL-27 was associated with a significantly lower colon weight and increased colon length (Fig. 1C) , resulting in a reduced colon weight:length ratio (P ¼ 0.005).
Oral administration of LL-IL-27 is presumed to act locally because there was no evidence of systemic absorption, as determined by IL-27 p28 ELISA (Fig. 1D) . Although mucosally delivered IL-27 was not measurable systemically, we observed a decrease in serum CRP in LL-IL-27-treated mice (Fig. 1E ). This can be attributed to indirect effects on liver production of CRP, possibly downstream of inflammatory cytokines such as IL-6, as will be discussed.
LL-IL-27 resulted in a significant reduction in total histology colitis score compared with LL-C ( Fig. 2A and D) , although this was surprisingly modest compared with clinical improvement. Assessment of the independent histological parameters of the composite score revealed significant protection against mucosal ulceration in those receiving LL-IL-27 (Fig. 2B) . We hypothesized that IL-27 may protect the epithelial barrier, shielding the innate immune system from contact with intestinal microbiota. IL-27 was previously shown to increase colonic epithelial cell proliferation and to promote epithelial wound restitution in vitro. 25 To explore this in vivo, we FIGURE 1. Oral delivery of IL-27 suppresses acute severe colitis. A, LL-IL-27 evokes a decreased DAI compared with LL-C; 5.8 versus 8.2 on day 1, 5.3 versus 8.9 on day 2, and 4.1 versus 8.2 on day 3, maximum 12, *P ¼ 0.001. B, LL-IL-27 led to significantly less weight loss than TNBS + LL-C or TNBS alone, P , 0.01 and P , 0.05 on days 2 and 3, respectively. Data in (A) and (B) combined from 3 separate experiments. n ¼ 14, 21, 25, 25 for ethanol, TNBS, TNBS + LL-C, and TNBS + LL-IL-27 groups, respectively. C, Macroscopic colitis score represented by colon weight (milligram) and length (centimeter). Colitis renders the colon shorter and heavier. Both parameters improved with LL-IL-27 versus LL-C; colon length, P ¼ 0.001 and colon weight, P ¼ 0.017. Data combined from 2 separate experiments. n ¼ 7, 16, 18, 19 for ethanol, TNBS, TNBS + LL-C, and TNBS + LL-IL-27, respectively. D, SJL/J colitic mice (2 mg of TNBS) receiving daily gavage of LL-IL-27 for 4 days (n ¼ 10) showed serum IL-27 of 2.9 pg/mL, indistinguishable from noncolitic untreated mice (n ¼ 8, 4.1 pg/mL), P ¼ 0.469 (t test). E, IL-27 provoked an improved systemic inflammatory response measured by serum CRP (day 2); LL-C versus LL-IL-27, P ¼ 0.019 (t test). Data from 1 experiment. n ¼ 5, 3, 10, 9, 10 for untreated, ethanol, TNBS, TNBS + LL-C, and TNBS + LL-IL-27, respectively. All data (A-E) presented as mean 6 standard error of the mean. assessed epithelial cell proliferation by Ki67 immunohistochemistry. Eliciting colitis increased epithelial proliferation by 50%, but there was no effect on proliferation index associated with LL-IL-27 (Fig. 2C) .
Our in vivo data show that oral IL-27 attenuates acute severe colitis when administered shortly after the time of colonic insult. An important question is whether preexposure to IL-27 could impact disease induction as a prophylactic effect. Mice were pretreated with LL-IL-27 for 2 weeks before intrarectal administration of TNBS. This did not affect acute colitis induction (Fig. 3) , suggesting that an active inflammatory microenvironment is required for IL-27 to suppress inflammation in the colonic mucosa.
IL-27 Reduces Colonic Neutrophil Infiltrate Associated with Decreased CXC Chemokine Expression
Previous studies have shown that lack of IL-27 signaling increased neutrophil influx to the site of acute bacterial infection in the peritoneal cavity 26 and lung. 24 This raised the question of FIGURE 2. Oral delivery of IL-27 leads to improved histologic colitis score and protection against ulceration in acute severe colitis. A, Cumulative histologic colitis score based on 5 parameters (degree of inflammatory cell infiltrate/mucosal ulceration/crypt hyperplasia/goblet cell depletion, presence of granuloma) with a maximum of 14. TNBS + LL-C versus TNBS + LL-IL-27, P ¼ 0.035. B, Degree of distal colonic mucosal ulceration score, graded on a scale of 0 to 4. 0 ¼ none, 1 ¼ erosion, 2 ¼ mild ulceration, 3 ¼ moderate ulceration, 4 ¼ severe ulceration. TNBS + LL-C versus TNBS + LL-IL-27, P ¼ 0.008. Data generated from randomly selected animals from 2 experiments. n ¼ 5,5,6,7 for ethanol, TNBS, TNBS + LL-C and TNBS + LL-IL-27, respectively. Mean 6 standard error of the mean. C, Epithelial proliferation index was assessed by Ki67 immunohistochemistry on paraffin-embedded distal colon sections. n ¼ 5/group from 2 experiments. Index derived from number of Ki67-positive cells/total number epithelial cells/high power field, expressed as percentage. Mean 6 standard error of the mean % from 5 HPF per sample used in analysis. Colitis evoked a significant increase in proliferation index across all groups compared with ethanol control; P ¼ 0.009, 0.001, and 0.002 for TNBS alone, TNBS + LL-C and TNBS + LL-IL-27, respectively. There was no significant difference between TNBS alone versus TNBS + LL-C versus TNBS + LL-IL-27 (P ¼ 0.243), t test. D, Representative distal colon photomicrographs of each experimental group. There is full-thickness necrosis of the mucosa and marked submucosal inflammation and edema in both the TNBS alone and TNBS + LL-C-treated mice. LL-IL-27 treatment significantly reduced mucosal necrosis and decreased inflammatory infiltrates. Slides were optically scanned with an Aperio AT2 digital slide scanner. Hematoxylin and eosin staining.
whether mucosal IL-27 might suppress neutrophil infiltration. To explore this as a potential mechanism, neutrophil and macrophage infiltration was assessed by myeloperoxidase and F4/80 immunohistochemistry, respectively. Induction of acute TNBS colitis led to a precipitous increase in mucosal neutrophils (P ¼ 0.001) and a modest increase in macrophages (P , 0.05). LL-IL-27 led to a significant reduction in myeloperoxidase + neutrophil infiltration into the colonic mucosa ( Fig. 4A and Neutrophils move to areas of acute inflammation through chemokine gradients; therefore, expression of several candidate chemokines in the distal colon was assessed. On day 2 post-TNBS instillation, CXCL1 and CXCL2, but not CXCL5, protein was significantly reduced in colitic mice treated with LL-IL-27 compared with LL-C (Fig. 4C) . CXCL2, a potent neutrophil chemokine, was taken forward in further investigation, and at the end of the treatment protocol (day 4 or time of death), the significant suppression persisted (Fig. 4D) .
Oral IL-27 Reduces CXCL2 Secretion in Ex Vivo Colon-Derived F4/80 + Macrophage
Macrophages are major producers of chemokines that induce a neutrophil influx. 27 The cellular source of CXCL2 in our acute TNBS colitis model was assessed by selecting F4/80 + cells from distal colon lamina propria cell suspension, on day 2 post-TNBS instillation, cultured for 24 hours to assess CXCL2 response. These colitis-derived F4/80 + macrophages secreted CXCL2, and this was significantly reduced in cells exposed to LL-IL-27 in vivo (Fig. 4E) .
IL-27 Does Not Directly Suppress Macrophage CXCL2 Expression Ex Vivo
Having shown that IL-27 suppressed chemokine expression by colonic macrophages in vivo, we next evaluated whether this was a direct effect by examining IL-27 responses of different macrophage preparations.
Bone marrow-derived macrophage expressed IL-27Ra (Fig. 5A) , demonstrating their capability to respond to IL-27. LPS stimulation provoked robust CXCL2 secretion. However, addition FIGURE 3. An active inflammatory microenvironment is required for oral IL-27 to suppress inflammation in the colonic mucosa. Preexposure to LL-IL-27 (10 oral gavages over 2-week period) before intrarectal instillation of 2 mg of TNBS (SJL/J 6-to 8-week-old male mice) did not impact acute colitis induction as measured by DAI (A), weight loss from starting weight (B), or macroscopic colitis score (C) (colon length and weight). Data presented combined from 2 separate experiments, n ¼ 10/group, as mean 6 standard error of the mean; analysis of variance on ranks and rank sum test for pairwise comparisons.
of recombinant IL-27 (rIL-27) for the 5-hour duration of LPS stimulation did not suppress this response (Fig. 5B) . To investigate whether the macrophage chemokine response was suppressed by priming with IL-27 before LPS challenge, bone marrow-derived macrophage were cultured in media containing rIL-27 for 48 hours before LPS stimulation. Again, exposure to LPS led to CXCL2 secretion, and this was not reduced by rIL-27 preexposure (Fig. 5C) .
To evaluate a different macrophage population, thioglycollate-induced peritoneal cells were examined, perhaps better representing the acute inflammatory macrophages in this in vivo colitis model. At day 4 after thioglycollate injection, the majority of cells were F4/80 + macrophages, representing F4/80 intermediate inflammatory and F4/80 high resident macrophages, coexisting with Ly6G + neutrophils (Fig. 5D ). Adherent cells were used as a macrophage enriched population and expressed IL-27Ra. As in bone marrow-derived macrophage, LPS induced robust CXCL2 expression, and this was not altered by the presence of rIL-27 (Fig. 5E) .
Overall, LPS-induced CXCL2 protein expression in macrophages was not inhibited by rIL-27 in 2 independent in vitro cell FIGURE 4. Oral IL-27 reduces colonic neutrophil infiltrate associated with decreased CXC chemokine expression. Distal colon inflammatory cell phenotype assessed by immunohistochemistry using myeloperoxidase (MPO) (A) and F4/80 positivity to identify neutrophils and macrophages (B), respectively. Data generated from randomly selected animals from 2 experiments. n ¼ 5,5,6,6,8 for untreated, ethanol, TNBS, TNBS + LL-C and TNBS + LL-IL-27, respectively. Mean 6 standard error of the mean. A, Treatment with IL-27 led to a significant reduction in MPO + neutrophil infiltration into the colonic mucosa (P ¼ 0.002, t test). B, F4/80 + macrophage infiltrate did not alter with LL-IL-27 treatment (P ¼ 0.250, t test). C, On day 2 after TNBS instillation, CXCL1 and CXCL2 but not CXCL5 protein (measured by ELISA and normalized to milligram total protein concentration) were significantly reduced in distal colon homogenate in colitic mice treated with LL-IL-27 compared with LL-C (P ¼ 0.026, P ¼ 0.038, and P ¼ 0.427 (t test), respectively). Data represents mean 6 standard error of the mean, generated from 2 separate experiments, n ¼ 10/group. D, This IL-27 associated reduction in CXCL2 expression persisted as measured later in the experimental protocol (day 4 or time of death), P ¼ 0.001 and P ¼ 0.003, compared with TNBS plus LL-C and TNBS alone, respectively. Mean 6 standard error of the mean, generated from one experiment, n ¼ 3, 3, 8, 8, 11 for untreated, ethanol, TNBS, TNBS + LL-C and TNBS + LL-IL27, respectively. E, Ex vivo-derived colitis-associated lamina propria F4/80 + macrophage cells secreted CXCL2 measured by ELISA after 24 hours culture at 378C (10 5 cells/200 mL), and this was significantly reduced in cells exposed in vivo to LL-IL-27, P ¼ 0.001 (t test). Data generated from 5 pooled distal colon samples per group. culture models, suggesting that this is not the direct mechanism for CXCL2 suppression in vivo.
However, it remained possible that macrophage responses would be site specific to the colon. To explore this, F4/80 + cells isolated from murine colon lamina propria were LPS stimulated for 24 hours, with or without rIL-27. As seen in the other macrophage culture models, LPS induced a striking increase in CXCL2 compared with unstimulated cells (Fig. 5F ). Once again, there was no significant IL-27 suppression of CXCL2 production in response to LPS. This supports the hypothesis that mucosal delivery of IL-27 does not directly interfere with the ability of colonic lamina propria macrophages to secrete CXCL2 after an inflammatory stimulus.
IL-27 Suppression of Acute Severe Colitis Is T Cell Independent
Because IL-27 inhibits several T-cell subsets, we assessed whether T-cell-mediated immunosuppression could be central to IL-27 effect in acute colitis.
TNBS colitis was evoked in Rag1-deficient (Rag1 2/2 ) mice that lack mature T and B cells and responses to LL-C or LL-IL-27 assessed. There was reduced disease severity evoked in the C57BL/6 strain of mice due to relative resistance to TNBS (compared with SJL/J strain). 28 LL-IL-27 led to a significantly improved DAI (Fig. 6A) . LL-IL-27-treated mice lost significantly less weight initially, although the difference between the groups narrowed during the protocol with a strong trend of improvement FIGURE 5. IL-27 does not directly suppress macrophage CXCL2 expression. To investigate the mechanism of IL-27-mediated immunosuppression, chemokine response in bone marrow-derived macrophage (A-C), thioglycollate-induced peritoneal macrophage (TPM) (D and E), and colonic lamina propria F4/80 + macrophage (F) were assessed. A, Greater than 90% of M-CSF-cultured bone marrow-derived cells expressed F4/80 and IL-27Ra. B, Bone marrow-derived macrophage were stimulated for 5 hours with various concentrations of LPS as labeled +/2rIL27 (100 ng/mL) and CXCL2 measured in supernatant by ELISA. Combined data from several experiments, generated from .3 wells/experimental condition. LPS resulted in a robust CXCL2 response, but there was no differential response in association with IL-27, t test. C, Exposure for .48 hours before LPS stimulation did not impact CXCL2 response, t test. D, Peritoneal cell phenotype day 4 after intraperitoneal thioglycollate injection. Cells expressed IL-27Ra. E, Adherent cells were stimulated with 50 ng/mL of LPS 6 100 ng/mL rIL27, for 5 or 72 hours. Again, LPS resulted in a robust CXCL2 response, but there was no differential response in association with IL-27. F, This was also seen in ex vivo colonic lamina propria F4/80+ cells stimulated for 24 hours with 50 ng/mL of LPS 6 100 ng/mL rIL27, t test. Results in C, E, and F presented from 1 experiment, with the same pattern of expression seen in repeat experiment. All data presented as mean 6 standard error of the mean.
in the LL-IL-27-treated group (Fig. 6B) . CXCL2 protein in distal colon homogenates was significantly inhibited by LL-IL-27 (Fig. 6C) , and there was a significant reduction in histologic colitis score (Fig. 6D) . Taken together, these data show that IL-27-mediated inhibition of acute colitis persists in Rag1-deficient mice, implying that the mechanism is T cell independent.
IL-27 Immunosuppression in Acute Severe Colitis Is IL-10 Dependent
It is known that IL-27 can induce the immunosuppressive cytokine, IL-10, 29, 30 from Tr1 T regulatory cells, 31 and other cell types, such as macrophages. 17 Our previous data revealed that LL-IL-27 evoked a significant colonic IL-10 response, from CD4 + CD8a intraepithelial T cells, and overall clinical improvement mediated by IL-27 was dependent on the production of this cytokine in a chronic enterocolitis model. 11 To evaluate whether IL-10 played a major role in the immunosuppressive function of IL-27 in the context of acute innate cell-driven colitis, we used an IL-10-deficient (C57BL/6 IL-10 2/2 ) mouse model in our experimental colitis protocol. There was no significant difference in DAI (Fig. 6E) or weight loss (Fig. 6F ) between mice treated with LL-C versus LL-IL-27. There was no reduction in CXCL2 (Fig. 6G) or FIGURE 6 . IL-27 immunosuppression in acute TNBS colitis is T cell independent and IL-10 dependent, evoking early IL-10 secretion in the colonic mucosa. A-D, Four milligrams of TNBS instilled intrarectally into Rag 2/-mice. Data combined from 2 separate experiments. n ¼ 10/group. There was a significant difference in DAI (A) in mice treated with LL-IL-27 compared with LL-C on days 1 and 2 (P ¼ 0.013 and P ¼ 0.040 respectively, t test) and degree of weight loss from baseline (B) on day 1 (P ¼ 0.019), then a trend just under significance on days 2 and 3 (P ¼ 0.06), t test. C, Distal colon homogenate CXCL2 protein was significantly reduced with LL-IL-27 (P ¼ 0.028), as was distal colon histologic score (D) (P ¼ 0.028, t test). E-H, Six milligrams of TNBS instilled intrarectally into IL-10 2/2 mice. Data combined from 2 separate experiments. n ¼ 8/group. E, DAI, P ¼ 0.237, 0.903, 0.681, respectively, on days 1, 2, and 3, LL-IL-27 versus LL-C, t test. F, Weight loss from baseline, P ¼ 0.727, 0.751, 0.716, respectively, on days 1, 2 and 3, LL-IL-27 versus LL-C, t test. G, CXCL2 protein in distal colon homogenate, P ¼ 0.959 and distal colon histologic score (H) (P ¼ 0.608, t test) were not significantly different in mice treated with LL-IL-27 compared with LL-C. I, On day 2 after TNBS instillation in SJL/J mice, there was a significant increase in distal colon IL-10 protein associated with IL-27 (P ¼ 0.01, t test). J, Later in the treatment protocol, at day 4 or time of death, this difference in IL-10 protein expression was not apparent, P ¼ 0.653. At both time points, n ¼ 10/group, combined data from 2 experiments. total histologic score (Fig. 6H ) associated with LL-IL-27. This suggests that IL-27-mediated immunosuppression in acute colitis is IL-10 dependent, and CXCL2 reduction is downstream of this IL-10 dependency.
Next, IL-10 protein expression was assessed in distal colon homogenate on either day 2 (Fig. 6I) or day 4/time of death after TNBS instillation (Fig. 6J) . On day 2, distal colonic IL-10 was increased by 25% in mice exposed to IL-27. Later, in the treatment protocol, there was no significant difference in mucosal IL-10 detected between colitic mice who received LL-C or LL-IL-27. This suggests that early in disease pathogenesis, L. lactis-delivered IL-27 hastens the immunoregulatory IL-10 response, increasing IL-10 in the colonic mucosal microenvironment, impacting clinical disease course and outcome.
IL-27 Induces Phosphorylated STAT-1 in Mucosal Epithelial Cells
To identify the cell type directly impacted by IL-27 treatment, immunohistochemistry was used to identify STAT-1 phosphorylation in response to orally administered LL-IL-27. Multifocal mucosal epithelial cells and scattered inflammatory cells within the lamina propria and submucosa showed strong positive nuclear labeling for phosphorylated STAT 1 (Fig. 7A) . This suggests that efficacy of LL-IL-27 is a consequence of both ¼ 3) . B, Cytokine gene expression profile in distal colon homogenate was assessed by Taqman RT-PCR assays (Applied Biosystems) and analyzed with ddCt method of relative quantification; normalization to endogenous GAPDH control and level of expression compared with ethanol control group. Data, combined from 2 experiments, presented as mean 6 standard error of the mean. Il6 (P ¼ 0.003), Il1b (P ¼ 0.001), and Tnf (P , 0.01) were significantly increased in TNBS-treated mice. Expression of Il6 was significantly reduced with LL-IL-27 compared with LL-C (P ¼ 0.036), whereas no such effect was seen for Il1b and Tnf. n ¼ 7, 10 to 13, 10 to 15, 10 to 15, for ethanol, TNBS alone, TNBS + LL-C and TNBS + LL-IL-27, respectively. C, Cytokine protein expression in distal colon homogenate measured by ELISA and normalized to milligram total protein. Combined data presented from 2 experiments as mean 6 standard error of the mean. n ¼ 5, 8 to 10, 7 to 10, 10, for ethanol, TNBS alone, TNBS + LL-C and TNBS + LL-IL-27, respectively. Protein expression of IL-6 (P ¼ 0.002), IL-1b (P ¼ 0.003), and tumor necrosis factor (P ¼ 0.031) were significantly reduced in the distal colon of colitic mice receiving LL-IL-27 treatment compared with LL-C.
immune and nonimmune cell-mediated effects. In keeping with this, IL-27 was previously shown to promote epithelial wound restitution in vitro. 25 As expected, gavage of LL-IL-27 in healthy noncolitic mice did not result in STAT-1 phosphorylation response, again demonstrating that an inflammatory microenvironment is required for LL-IL-27 immunosuppression.
IL-27 Significantly Reduces Proinflammatory Cytokine Profile In Vivo
Gene expression of proinflammatory cytokines were assessed in distal colon homogenate, namely, Il6, Il1b, Tnf, Il13, Il12, Ifng, Il17a, and Il22, along with the regulatory T-cell-associated transcription factor Foxp3. The majority of these genes were expressed at low abundance or undetectable and not investigated further. Il6, Il1b, and Tnf were significantly increased in all TNBS-treated mice compared with ethanol controls (Fig. 7B) . Il6 expression was significantly lower in mice treated with LL-IL-27 compared with LL-C. No differential expression of Il1b or Tnf was seen with LL-IL-27 treatment.
In contrast, distal colon protein expression of IL6, IL1b, and tumor necrosis factor were significantly reduced in colitic mice receiving LL-IL-27 treatment (Fig. 7C) , highlighting a discrepancy between gene and protein expression for the latter 2 cytokines. This suggests potential influences on translational or posttranslational regulation. Thus, we hypothesized that IL-27 may inhibit the inflammasome as a mechanism of immunosuppression. However, there was no impact on the expression of distal colon il-18 or inflammasome components (Nlrp3, Caspase-1, and Asc) or LPS-induced IL1b secretion from in vitro macrophage preparations (see Fig. 2 , Supplemental Digital Content 2, http://links.lww.com/IBD/B651), suggesting that IL-27 does not directly influence acute colonic inflammasome activation in vivo.
DISCUSSION
Our data show a novel immunosuppressive activity of the cytokine IL-27 in acute severe colitis, directed toward gut mucosal innate immune responses. Mucosal delivery of IL-27 reduced clinical parameters of colonic disease activity, repressed systemic inflammatory response, and improved colitis histology score. LL-IL-27 improved mucosal ulceration. This is important because mucosal healing is defined by the absence of ulcerated lesions in the gut mucosa during endoscopy, and this represents a primary end point in assessing the effectiveness of inflammatory bowel disease therapy.
The mechanism of IL-27-directed immunosuppression was multifactorial. These data represent first in field evidence of IL-27-evoked reduction in colonic mucosal neutrophil infiltrate, associated with a decreased CXC chemokine gradient. This was T cell independent and IL-10 dependent, with early enhanced mucosal IL-10. IL-27 also significantly attenuated proinflammatory cytokine protein expression. Although there was no evidence of direct impact on epithelial cell proliferation, IL-27 provoked an epithelial phosphorylated STAT-1 response. For the first time, we have revealed that IL-27 attenuates acute immune responses in the colon in vivo in a noninfective, genetically intact host.
IL-27-evoked reduction in myeloid cell infiltrate has been reported in different body sites, identified through genetic manipulation of IL-27 receptor signaling. Atherosclerotic prone Ldlr 2/2 mice had attenuated disease with hematopoietic cell IL-27Ra deficiency, mediated partly through reduced plaque chemokine gradient and infiltration of myeloid cells. 32 Ebi3 2/2 mice demonstrated reduced granulocyte flux to acute peritonitis. 26 When IL-27 receptor signaling was interrupted by genetic deficiency or antibody blocking, mice with systemic sepsis secondary to cecal puncture ligation and exposed to a secondary pneumonic bacterial insult exhibited enhanced neutrophil infiltrate to the lungs. This was associated with an increased chemokine expression including CXCL2 and proinflammatory mediators, such as IL-6, tumor necrosis factor, and IL1b. 24 This IL-27-mediated blunting of granulocyte response was deleterious overall and associated with the inability to resolve the secondary bacterial infection.
Neutrophils are necessary for the efficient resolution of acute microbial attack through a variety of mechanisms. 33 The suppression of neutrophil influx by IL-27 complicates IL-27 therapy for application to human disease. However, LL-IL-27 represents a localized rather than systemic therapy, delivered orally to act directly on the inflamed colonic mucosa, with no evidence of systemic IL-27 absorption as reported here and in our previous publication. 11 The balance of beneficial to deleterious IL-27 inhibition of innate immunity appears site specific. Thus, IL-27 is beneficial in the circumstance of acute noninfective colitis, by limiting granulocyte-directed tissue damage, release of proinflammatory mediators, and activation of downstream adaptive immune responses.
CXCL2 is a potent neutrophil chemokine, secreted mainly by monocytes and macrophages, in response to LPS stimulation. 27 There is existing evidence that IL-27 can modulate the functional capacity of macrophages and other innate cells. It is unclear whether IL-27 effects on innate cells are proinflammatory or anti-inflammatory, and it appears that the outcome is dependent on stimulus, cell type, and surrounding or experimental microenvironment, 14 akin to its pleiotropic effect on T-cell biology. For example, IL-27 can enhance proinflammatory cytokine and chemokine expression from blood-derived human monocytes cultured and stimulated in vitro. 34, 35 In the gut, host or recipient IL-27R-knockout mice, with or without genetic silencing of TCR revealed a role of IL-27-induced, antigen-presenting cellderived, cytokine-mediated Th17 responses in T-cell-driven colitis. 36 Conversely, lung macrophages from IL-27Ra-knockout mice exert enhanced proinflammatory cytokine and chemokine secretion, along with increased antimicrobial killing capacity, 24 exemplifying a suppressive activity of IL-27 on innate immune cells. Iyer et al 17 revealed that macrophage IL-10 secretion in response to LPS or type I interferons is dependent on endogenous IL-27 signaling. Therefore, it was reasonable to speculate that our orally delivered IL-27 may suppress the proinflammatory function of the colonic macrophage population. Indeed, our data suggest that colonic macrophages are a potent source of CXCL2 during acute colitis, and this was blunted by in vivo exposure to IL-27. We did not find evidence to support a direct immunosuppressive effect of IL-27 on macrophage chemokine response, despite using 3 independent ex vivo macrophage culture models including colonic macrophages.
We then assessed the involvement of T cells in the IL-27-mediated immunosuppression in this acute colitis model. IL-27 inhibits Th2 and Th17 responses, 13,14 although this was not likely to be prominent in our acute model given the rapid onset of pathology. T cells present in the normal colonic mucosa are part of the "physiological immunity" that evokes tolerance to luminal antigens and appropriate response to pathogenic insult. IL-27 is known to promote T regulatory cell subsets. 31, 37 However, in our model, IL-27 immunosuppression of innate cell-driven colonic pathology was T cell independent.
We acknowledge that the direct cell target of orally delivered IL-27 in acute colitis remains elusive. We predict that IL-27 in acute severe colitis acts on epithelial cells and inflammatory cells of unknown phenotype. There are several immune cell types that may, independently or in conjunction, act in response to exogenous IL-27, such as neutrophils, DCs, or innate lymphoid cells and, although outside the scope of this current study, warrants further investigation to reveal novel biologic functions of IL-27. Neutrophils can secrete chemokines and attract an increasing neutrophil influx. 38 IL-27 can inhibit neutrophil reactive oxygen species production, 16, 19 reduce their expression of the surface integrin Mac-1, 16, 19 and provoke short-lived IL-1b secretion either independently 16 or in response to bacterial challenge. 19, 24 IL-27 receptor deficiency led to enhanced neutrophil intracellular bacterial killing. 24 IL-27 affects neither neutrophil survival nor apoptosis. 16 Another potential cell candidate is DCs. Human immature DCs exposed to IL-27 displayed reduced antigen-presenting capacity. 22 IL-27 provokes DC-derived IL-10 and suppresses downstream Th1 and Th17 response. 20, 21 This mechanism impacts disease outcome in central nervous system autoimmune pathology, with vaccination of IL-27 primed DCs attenuating murine experimental autoimmune encephalomyelitis. 21 Another potential cell candidate is colonic epithelial cells, as this cell compartment can secrete chemokines, 39, 40 and our results indicate that these cells strongly express phosphorylated STAT1 in response to mucosally delivered LL-IL-27 in vivo.
These data confirm the potential for oral L. lactis IL-27 to be a potential rescue medical therapy in acute severe colitis. L. lactis is a nonpathogenic, noncolonizing, and nontransmissible food grade bacterium. The use of this bacterium as a mucosal delivery system for therapeutic proteins and vaccines has been reviewed elsewhere. [41] [42] [43] We showed previously that orally delivered IL-27 attenuates chronic T-cell-derived colonic inflammation 11 and now present novel evidence to show efficacy toward acute innate cell-derived colonic pathology, highlighting translational impact as a new or adjunct medical treatment strategy in acute severe colitis.
